Showing 4031-4040 of 6035 results for "".
- Opthea Publishes Phase 2b Trial Data for Wet AMDhttps://modernod.com/news/opthea-publishes-promising-phase-2b-trial-data-for-wet-amd/2482685/Opthea announced new data from the phase 2b clinical trial using sozinibercept to treat wet age-related macular degeneration (AMD). The results were published in the peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging (OSLI) Retina. Opthea’s complete phase 3 wet AMD
- Altris AI Launches Advanced Optic Disc Analysis for Glaucomahttps://modernod.com/news/altris-ai-launches-advanced-optic-disc-analysis-for-glaucoma-complementing-gcc-asymmetry-analysis/2482683/Altris AI, a provider of AI OCT scan analysis for the detection of a range of retina pathologies and biomarkers, announced the launch of an advanced glaucoma 'Optic Disc Analysis' module. To address need to improve timely and accurate gl
- Opus Genetics Doses First Pediatric Patient in Phase 1/2 Trial for OPGx-LCA5 Gene Therapyhttps://modernod.com/news/opus-genetics-doses-first-pediatric-patient-in-phase-12-trial-for-opgx-lca5-gene-therapy/2482675/Opus Genetics announced the first pediatric patient has been dosed in its ongoing phase 1/2 clinical trial evaluating OPGx-LCA5, its investigational gene therapy for Leber congenital amaurosis (LCA). Initial data from the pediatric cohort is expected to be shared by Q3
- World’s First AI-Powered Cardiovascular Retinal Screening to be Launched in the UKhttps://modernod.com/news/worlds-first-ai-powered-cardiovascular-retinal-screening-to-be-launched-in-the-uk/2482674/Heart Eye has unveiled AI-powered cardiovascular screening technology using retinal imaging in the UK. The company says the technology delivers patients’ cardiovascular disease risk results in just 3 minutes. The technology, called '
- Oculus Launches Myopia Software Package on the Pentacam AXL Wavehttps://modernod.com/news/oculus-launches-myopia-software-package-on-the-pentacam-axl-wave/2482670/Oculus is launching the Myopia Software Package on the Pentacam AXL Wave. The new software is designed to offer optometrists improved accuracy, ease, and safety in their myopia management, comprehensive screening, and ortho-k fitting with one device. The Pentacam AXL
- Alcon Announces US Launch of Voyager DSLT for Glaucoma and Ocular Hypertensionhttps://modernod.com/news/alcon-announces-us-launch-of-voyager-dslt-for-glaucoma-and-ocular-hypertension/2482669/Alcon announced the full US commercial availability of Voyager DSLT, the first and only direct selective laser trabeculoplasty device (DSLT). According to Alcon, Voyager DSLT may accelerate the adoption of laser as a first-line therapy, making the treatment availabil
- FDA Clears New World Medical's VIA360 Surgical Systemhttps://modernod.com/news/fda-clears-new-world-medicals-via360-surgical-system/2482667/New World Medical has received 510(k) clearance from the FDA for its VIA360 Surgical System for the delivery of controlled amounts of viscoelastic fluid during ophthalmic surgeries. The VIA360, which is also indicated to cut trabecular meshwork tissue during trabecul
- EssilorLuxottica Acquires Canadian Med-Tech Start-Up Cellviewhttps://modernod.com/news/essilorluxottica-acquires-canadian-med-tech-start-up-cellview/2482659/EssilorLuxottica has acquired Cellview Imaging, a Canadian start-up specializing in diagnostic via retinal imaging. Financial terms of the deal were not disclosed. Based in Toronto, Cellview designs and manufactures diagnostic imaging instruments. Currently distributed in North Ame
- DigitalOptometrics to Preview 'World’s First Autonomous Slitlamp' at Vision Expo East 2025https://modernod.com/news/digitaloptometrics-to-preview-worlds-first-autonomous-slitlamp-at-vision-expo-east-2025/2482655/DigitalOptometrics has announced the launch of what it is calling the world’s first and most advanced autonomous slitlamp with remote control capabilities at Vision Expo East (VEE) 2025 in Orlando. In collaboration with SlitLED, DigitalOptometrics will demonstrate t
- 4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Studyhttps://modernod.com/news/4dmt-presents-positive-52-week-results-from-phase-2b-cohort-of-prism-wet-amd-study/2482654/4D Molecular Therapeutics (4DMT) announced positive initial interim 52-week data from the phase 2b population extension cohort of the PRISM clinical trial evaluating 4D-150 in a broad wet age-related macular degeneration (AMD) patient population. Additional data were provided on the durabili